Point State Capital LP Clovis Oncology, Inc. Transaction History

Point State Capital LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$12.81 - $25.67 $2.48 Million - $4.97 Million	-193,712 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$17.66 - $30.28 $13.1 Million - $22.5 Million	-743,964 Reduced 79.34%	193,712 $4.81 Million
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $23.3 Million - $65.5 Million	-2,005,228 Reduced 68.14%	937,676 $16.8 Million
Q3 2018 Nov 14, 2018	SELL	$29.37 - $49.48 $3.02 Million - $5.09 Million	-102,906 Reduced 3.38%	2,942,904 $86.4 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $21.2 Million - $31.4 Million	503,687 Added 19.81%	3,045,810 $138 Million

Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $18.3 Million - $24.7 Million	-364,726 Reduced 12.55%	2,542,123 $134 Million
Q4 2017 Feb 14, 2018	BUY	$57.69 - $84.58 $31.2 Million - $45.7 Million	540,400 Added 22.84%	2,906,849 $198 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $24.9 Million - $31.5 Million	371,310 Added 18.61%	2,366,449 $195 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,995,139	1,995,139 $187 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

Stay updated on Point State Capital LP with notifications on news.